Item 4 — Purpose of Transaction
On April 1, 2026, the Issuer issued the Note to HH with an original principal amount of $2,767,756 in exchange for a note that had been previously issued by the Issuer to Steve Hall ("Hall") and that Hall had sold to HH (the "Existing Hall Note"). The Note has a maturity date of 24 months from its date of issuance and was issued pursuant to a Note Purchase Agreement (the "Note Purchase Agreement"), dated as of April 1, 2026, among the Issuer, Hall, and HH. Under the Note Purchase Agreement, the Existing Hall Note was amended and restated in the form of the Convertible Promissory Note. The Note Purchase Agreement contains customary representations, warranties, covenants, conditions and indemnification obligations of the parties. Under the Convertible Promissory Note, HH may convert all or a portion of the outstanding principal amount of the Convertible Promissory Note into shares (the "Conversion Shares") of the Issuer's common stock, par value $0.0001 per share ("Common Stock") at any time before the outstanding principal amount of the Convertible Promissory Note is paid in full. The number of shares of Common Stock issuable upon conversion of the Convertible Promissory Note will be determined by dividing the principal amount to be converted by the conversion price in effect on the conversion date (the "Conversion Price"). The initial Conversion Price as of the Convertible Promissory Note's date of issuance was $0.12, which Conversion Price is subject to adjustment in the event of dividends or distributions made with respect to the Common Stock and stock splits, reverse stock splits or other subdivisions or combinations of the Common Stock. Additionally, the Conversion Price will be adjusted in connection with any issuances by the Issuer of Common Stock or securities convertible or exchangeable into Common Stock at a purchase, exercise or conversion price that is lower than the Conversion Price, in which case the Conversion Price will be adjusted to be equal to such lower price. The Convertible Promissory Note (and/or, to the extent the Convertible Promissory Note has been converted, the Conversion Shares issued upon conversion) may be repurchased by Hall from HH if (A) on the two year anniversary of issuance, the Issuer has not received at least an aggregate of $1.0 million in gross proceeds from the sale of equity securities or securities convertible into equity securities (a "Subsequent Financing"), or (B) the OTC Market Group Inc. places a "caveat emptor" designation on the Issuer's publicly traded securities, in each case subject to a 30 day cure period. The repurchase right will terminate on the earlier to occur of (A) the consummation of a Subsequent Financing, or (B) if such right is not exercised within 15 days of an applicable triggering event. On April 1, 2026, the Issuer, Hall, and HH entered into an Investor Rights Agreement (the "Investor Rights Agreement"), pursuant to which the Issuer agreed to file a registration statement registering the resale of all shares of Common Stock held by HH and shares of Common Stock issuable upon the exercise or conversion of securities held by HH (the "Registrable Securities"). The Issuer agreed to file a registration statement within 30 days following a request by HH and to use its reasonable best efforts to cause the registration statement to be declared effective within 75 days. The Investor Rights Agreement also grants certain piggyback registration rights to HH. Additionally, the Investor Rights Agreement requires that the Issuer increase the size of its Board of Directors (the "Board") from one to five members, to appoint four individuals to the Board as designated by HH, and to nominate and recommend such designees for election to the Board at future meetings of the Issuer's stockholders. On March 31, 2026, the Board approved the conditional appointment of Mr. Sumichrast, Sim Farar, Nathan Bradley Fleisher, and Ralph Olson as 14F Directors, which appointment shall become effective ten days after the filing and transmission of an Information Statement on Schedule 14f-1 by the Issuer. Effective as of April 1, 2026, the Board appointed David Wachsman as the President of the Issuer and Quinton Byron Hamlet as the Chief Financial Officer of the Issuer. Each of Messrs. Wachsman and Hamlet are members of HH, but do not have voting or dispositive power over the shares of Common Stock beneficially held by HH. As a substantial owner of shares in the Issuer, HH may have influence over the corporate activities of the Issuer that require the vote of the shareholders of the Issuer, including those that may relate to the transactions described in clauses (a) through (j) of Item 4 of Schedule 13D. To the extent the actions described herein may be deemed to constitute a "control purpose" with respect to the Securities Exchange Act of 1934, as amended, and the regulations thereunder, the Reporting Persons have such a purpose. Except as noted in this Schedule 13D, the Rep